The prices charged by drug manufacturers to wholesalers and distributors (commonly referred to as exmanufacturers prices) in the United States are 1.8 times higher than in other countries for the top drugs by total expenditures separately paid under Medicare Part B. U.S. prices were higher for most of the drugs included in the analysis, and U.S.
Prescription Drugs & Other Medical Products
Drugs and other medical products greatly impact human health and the health care system. ASPE conducts a variety of research in this area, including work related to medical product development and regulation; medical product markets, pricing and competition; prescription drug benefits and spending on medical products; medical product supply chains; and medical product safety.
Noteworthy
Reports
Displaying 91 - 100 of 164. 10 per page. Page 10.
Advanced SearchCost Drivers in the Development and Validation of Biomarkers Used in Drug Development
Despite the increasing investment and interest in drug development, the amount of time and resources needed to develop a new drug continues to rise. Biomarkers are an important tool with the potential to decrease the time, cost, and failure rate of drug development.
Addressing the Opioids Crisis: Data Sources and Linking Strategies
This report highlights key research questions and identifies opportunities to use existing data sources and implement data-linking strategies that can support the HHS five point strategy to combat the opioid crisis.
ASPE Data Point
Data point: Prescription Pharmaceutical Price Changes since the Release of the President’s Drug Pricing Blueprint
Using manufacturer-reported prescription pharmaceutical prices, we observe that the number of price increases has been reduced considerably since the release of the President’s Drug Pricing Blueprint, compared to the same time period in the year prior.
State and Local Policy Levers for Increasing Treatment and Recovery Capacity to Address the Opioid Epidemic: Final Report
This report summarizes financing and workforce policies that can be used by states to expand treatment access and capacity for opioid use disorder (OUD), focusing especially on medication-assisted treatment (MAT).
ASPE Data Point
Data Point: Savings Available Under Full Generic Substitution of Multiple Source Brand Drugs in Medicare Part D
ASPE analyzed Part D prescription drug event data from 2016 to estimate spending on brand drugs with generic therapeutic equivalents.
Economic Opportunity and the Opioid Crisis: Geographic and Economic Trends
This study examines relationships between indicators of economic opportunity and the prevalence of prescription opioids and substance use in the United States. We have three primary findings:
Substance Use, the Opioid Epidemic and the Child Welfare Caseloads: Methodological Details from a Mixed Methods Study
This brief describes the research methods used to produce the findings in Substance Use, the Opioid Epidemic, and Child Welfare Caseloads: A Mixed Methods Study. It is a part of a series of briefs that discuss different aspects and issues surrounding the relationship between substance use disorders and the child welfare system.
Substance Use, the Opioid Epidemic and the Child Welfare System: Key Findings from a Mixed Methods Study
This study examined the relationship between parental substance misuse and child welfare caseloads, which began rising in 2012 after more than a decade of decline.
Research to Address the Opioid Crisis: Approaches to Data Linkage
To combat the public health crisis associated with the opioid overdose epidemic, HHS will host an Opioid Code-a-Thon on December 6-7, 2017 to develop data driven solutions to combat the opioid epidemic. This Data Brief presents an overview of the data sources that could be leveraged to study the opioid crisis within each of the five HHS strategic areas, highlights some of the key res